Browse by Clinical Topic:

Featured CME/CE Content:
neuroscienceCME Editors' Picks:

Dismantling Disparities in Primary Immunodeficiency Care: Building Blocks to Equity

Premiere Date: Wednesday, January 25, 2023

This activity offers CE credit for:

  1. ABIM (MOC)
  2. Family Physicians (AAFP)
  3. Medicine (accme)
  4. Nursing (ANCC)
  5. Pharmacy (acpe)
  6. PA (aapa)
  7. Other

All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™

Credit Expiration Date:
Thursday, January 25, 2024
Note: Credit Is No Longer Available


Niraj C. Patel, MD, MSNiraj C. Patel, MD, MS (Moderator)
Associate Professor
Division of Allergy and Immunology
Duke University Medical Center
Durham, NC

Antoine Azar, MDAntoine Azar, MD 
Clinical Director, Division of Allergy and Clinical Immunology
Director, Adult Primary Immunodeficiency Center
Associate Professor of Medicine
Johns Hopkins School of Medicine
Baltimore, MD

Vivian Hernandez-Trujillo, MDVivian Hernandez-Trujillo, MD 
Founder, Allergy and Immunology Care Center of South Florida
Medical Director, Division of Allergy and Immunology, Nicklaus Children's Hospital
Clinical Professor of Pediatrics
Herbert Wertheim School of Medicine, Florida International University
Miami, FL

Ilana Jacqueline, Ilana Jacqueline,  
Patient Advocate
Author of Surviving and Thriving with an Invisible Chronic Illness

Statement of Need

In the United States, approximately 250,000 people have been diagnosed with a primary immunodeficiency (PI) disorder, and these patients have increased vulnerability to severe infections as well as lifelong impairment. Despite the severity of this disorder, however, there are significant disparities in diagnosis, treatment, and outcomes for patients diagnosed with PI who are from racial and ethnic underserved populations, as well as those of lower socioeconomic status.

This CME Outfitters Webcast will focus on addressing these persistent health disparities. Expert faculty will engage the audience in the development of improved skills in identifying the signs and symptoms of PI to reduce diagnostic delays, emphasize the importance of implementing consistent, guideline-directed treatment plans for all patients, and advise on the importance of effective patient-clinician communication and education.

Learning Objectives

At the end of this CE activity, participants should be able to:

  • Identify signs and symptoms of PI to decrease diagnostic delays, especially in underserved populations.
  • Implement evidence-based treatment strategies to optimize PI management.
  • Educate and inform patients (and clinicians) about PI from the patient’s perspective.

Financial Support

Supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.

Target Audience

Physicians, nurse practitioners, PAs, infusion nurses, pharmacists, or other clinicians in primary care, as well as any clinician who manages or treats patients with PI.

Credit Information

AAFP Credit (Family Physicians):
The AAFP has reviewed Dismantling Disparities in Primary Immunodeficiency Care: Building Blocks to Equity and deemed it acceptable for up to 1.00 Enduring Materials, Self-Study AAFP Prescribed credits. Term of Approval is from 01/25/2023 to 01/25/2024. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAFP Prescribed credit is accepted by the American Medical Association as equivalent to AMA PRA Category 1 Credit™ toward the AMA Physician's Recognition Award. When applying for the AMA PRA, Prescribed credit earned must be reported as Prescribed, not as Category 1.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 medical knowledge MOC point in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Learning formats:
Enduring material

Royal College MOC:
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

MIPS Improvement Activity:
This activity counts towards MIPS Improvement Activity requirements under the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Dr. Patel reports the following financial relationships:

Advisory Board: CSL Behring; Horizon Therapeutics; and Takeda Pharmaceuticals U.S.A., Inc.

Consultant: Horizon Therapeutics

Grants: CSL Behring

Research Support: CSL Behring and Takeda Pharmaceuticals U.S.A., Inc.

Dr. Azar reports the following financial relationships:

Advisory Board: Grifols and Opinose

Consultant: Argenx and Takeda Pharmaceuticals U.S.A., Inc.

Grants and Research Support: Argenx; Grifols; and X4 Pharmaceuticals, Inc.

Speakers Bureau: ADMA Biologics, Inc. and Grifols

Dr. Hernandez-Trujillo reports the following financial relationships:

Advisory Board: Aimmune Therapeutics; Regeneron Pharmaceuticals Inc.; Sanofi; Takeda Pharmaceuticals U.S.A., Inc.; and US WorldMeds

Consultant: Amgen Inc.; CSL; Kaleo, Inc.; National Peanut Board; Pharming; and Takeda Pharmaceuticals U.S.A., Inc.

Grants: Immune Deficiency Foundation

Speakers Bureau: CSL Behring and Takeda Pharmaceuticals U.S.A., Inc

Ms. Jacqueline reports no financial relationships to disclose.

The following CME Outfitters peer reviewer and staff have no financial relationships:

  • Elizabeth Naber, MSN, RN, CCRN-K, CNRN, TCRN (peer reviewer)
  • Morgan Stockberger, MD (planning committee)
  • Warren Beckman (planning committee)
  • Susan H. Yarbrough, CHCP (planning committee)
  • Sandra Caballero, PharmD (planning committee)
  • Sharon Tordoff (planning committee)

  • Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

    Questions about this activity? Call us at 877.CME.PROS (877.263.7767).


    Home      |      Register/Log In      |      Activities      |      Communities of Practice      |      About      |      Download